LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 985

Search options

  1. Article ; Online: Anti-amyloid therapies work for Alzheimer's disease.

    Hardy, John

    Brain communications

    2023  Volume 5, Issue 4, Page(s) fcad204

    Language English
    Publishing date 2023-07-17
    Publishing country England
    Document type Journal Article
    ISSN 2632-1297
    ISSN (online) 2632-1297
    DOI 10.1093/braincomms/fcad204
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Book ; Online: Organic Electronics From Synthesis To Applications

    George Hardy, John / Young Lee, Jae / Augusto Bortolotti, Carlo / Knoll, Wolfgang / Biscarini, Fabio

    2020  

    Keywords Science: general issues ; organic electronics ; carbon nanotubes ; fullerene ; graphene ; conjugated polymer ; conducting polymer ; green electronics ; biodegradable electronics ; bioelectronics ; biosensing
    Size 1 electronic resource (143 pages)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021230155
    ISBN 9782889634538 ; 2889634531
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Reply: Unblinding in the lecanemab trial in Alzheimer's disease.

    Hardy, John / Mummery, Catherine

    Brain : a journal of neurology

    2023  Volume 146, Issue 11, Page(s) e101

    MeSH term(s) Humans ; Alzheimer Disease/drug therapy
    Chemical Substances lecanemab (12PYH0FTU9)
    Language English
    Publishing date 2023-09-07
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/awad201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.26: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Reply: Lecanemab: turning point, or status quo? An ethics perspective.

    Hardy, John / Mummery, Catherine

    Brain : a journal of neurology

    2023  Volume 146, Issue 9, Page(s) e73

    MeSH term(s) Humans ; Alzheimer Disease ; Decision Making ; Amyloidogenic Proteins
    Chemical Substances lecanemab (12PYH0FTU9) ; Amyloidogenic Proteins
    Language English
    Publishing date 2023-06-09
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/awad102
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.26: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?

    Hardy, John / Mummery, Catherine

    Brain : a journal of neurology

    2023  Volume 146, Issue 4, Page(s) 1240–1242

    MeSH term(s) Humans ; Alzheimer Disease/therapy ; Amyloid beta-Peptides ; Amyloid ; Amyloidogenic Proteins
    Chemical Substances Amyloid beta-Peptides ; Amyloid ; Amyloidogenic Proteins
    Language English
    Publishing date 2023-02-19
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/awad049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.26: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.

    Hardy, John / Schott, Jonathan M

    Neurology

    2023  Volume 102, Issue 3, Page(s) e208096

    Abstract: In the last 2 years, there have been 3 successful trials of antiamyloid antibodies in Alzheimer disease (AD): aducanemab, now controversially US Food and Drug Administration-approved under the accelerated approval ... ...

    Abstract In the last 2 years, there have been 3 successful trials of antiamyloid antibodies in Alzheimer disease (AD): aducanemab, now controversially US Food and Drug Administration-approved under the accelerated approval pathway
    MeSH term(s) United States ; Humans ; Amyloidogenic Proteins ; Diagnostic Imaging ; Amyloid beta-Peptides ; Inflammation ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/genetics
    Chemical Substances donanemab ; Amyloidogenic Proteins ; Amyloid beta-Peptides
    Language English
    Publishing date 2023-12-28
    Publishing country United States
    Document type Editorial
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000208096
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 18: Show issues
    Zs.MO 374: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk.

    Hardy, John

    Frontiers in neuroscience

    2019  Volume 13, Page(s) 1304

    Abstract: As we identify the loci involved in late onset neurodegenerative disease, we are finding that the majority of them are involved in damage response processes. In this short review, I propose that it is partly a failure in these damage response processes ... ...

    Abstract As we identify the loci involved in late onset neurodegenerative disease, we are finding that the majority of them are involved in damage response processes. In this short review, I propose that it is partly a failure in these damage response processes which underlie late onset disease and that the resultant pathology is a marker of the type of damage response which has failed: microglial clearance of damaged neuronal membranes in Alzheimer's disease (AD), ubiquitin proteasome clearance in the tauopathies, and lysosomal clearance in Parkinson's disease (PD). In this review, I outline this relationship. This article is not intended as a comprehensive review of the cell biology of any of these disorders but rather a summary of the evidence that the genetics and pathology of these disorders appear to point, in each case, to the removal of misfolded proteins as a critical process in disease pathogenesis.
    Language English
    Publishing date 2019-12-05
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2411902-7
    ISSN 1662-453X ; 1662-4548
    ISSN (online) 1662-453X
    ISSN 1662-4548
    DOI 10.3389/fnins.2019.01304
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Genome-wide association studies for Alzheimer's disease: bigger is not always better.

    Escott-Price, Valentina / Hardy, John

    Brain communications

    2022  Volume 4, Issue 3, Page(s) fcac125

    Abstract: As the size of genome-wide association studies increase, the number of associated trait loci identified inevitably increase. One welcomes this if it allows the better delineation of the pathways to disease and increases the accuracy of genetic prediction ...

    Abstract As the size of genome-wide association studies increase, the number of associated trait loci identified inevitably increase. One welcomes this if it allows the better delineation of the pathways to disease and increases the accuracy of genetic prediction of disease risk through polygenic risk score analysis. However, there are several problems in the continuing increase in the genome-wide analysis of 'Alzheimer's disease'. In this review, we have systematically assessed the history of Alzheimer's disease genome-wide association studies, including their sample sizes, age and selection/assessment criteria of cases and controls and heritability explained by these disease genome-wide association studies. We observe that nearly all earlier disease genome-wide association studies are now part of all current disease genome-wide association studies. In addition, the latest disease genome-wide association studies include (i) only a small fraction (∼10%) of clinically screened controls, substituting for them population-based samples which are systematically younger than cases, and (ii) around 50% of Alzheimer's disease cases are in fact 'proxy dementia cases'. As a consequence, the more genes the field finds, the less the heritability they explain. We highlight potential caveats this situation creates and discuss some of the consequences occurring when translating the newest Alzheimer's disease genome-wide association study results into basic research and/or clinical practice.
    Language English
    Publishing date 2022-05-17
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2632-1297
    ISSN (online) 2632-1297
    DOI 10.1093/braincomms/fcac125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article: Development of bespoke hardware and software to enable testing of a novel method of managing the charge and discharge of series-connected battery packs.

    Hardy, John / Steggall, John / Hardy, Peter

    MethodsX

    2023  Volume 11, Page(s) 102294

    Abstract: The novel feature of the method of battery management under development and testing is that routine balancing of the cells is eliminated throughout the service life of the battery pack. This requires preparation of the battery cells and configuration of ... ...

    Abstract The novel feature of the method of battery management under development and testing is that routine balancing of the cells is eliminated throughout the service life of the battery pack. This requires preparation of the battery cells and configuration of the rigs in such a way as to ensure that the cells are accurately balanced on assembly and that thereafter there is no cell-to-cell variation in charge current or load at any time, measured to a low microamp level. In addition, the method requires a special charge control algorithm which was devised in order to accommodate cell-to-cell variations in capacity and dynamic response. Comprehensive experimental testing of this method, which is fully described in the associated paper (Hardy et al., 2023), required the development of hardware and software which would combine the necessary functions of a battery test rig and a battery management system capable of carrying out the special method of charge control described below. These included:•The automated control of contactors, loads and chargers to perform multiple charge/discharge cycles to predetermined patterns of current and maximum and minimum cell voltages.•Monitoring of cell voltages, current and temperature and the provision of test and diagnostic data.•Performing the safety functions of a Battery Management System to ensure that no cell was permitted to exceed limitations of current, voltage or temperature. The hardware and software were developed through three phases of testing with the operational principles (but not all the hardware and software elements) carrying over from one phase to the next.
    Language English
    Publishing date 2023-07-20
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2830212-6
    ISSN 2215-0161
    ISSN 2215-0161
    DOI 10.1016/j.mex.2023.102294
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Single-cell RNA sequencing analysis of human Alzheimer's disease brain samples reveals neuronal and glial specific cells differential expression.

    Soreq, Lilach / Bird, Hannah / Mohamed, Wael / Hardy, John

    PloS one

    2023  Volume 18, Issue 2, Page(s) e0277630

    Abstract: Alzheimer's disease is the most common neurological disease worldwide. Unfortunately, there are currently no effective treatment methods nor early detection methods. Furthermore, the disease underlying molecular mechanisms are poorly understood. Global ... ...

    Abstract Alzheimer's disease is the most common neurological disease worldwide. Unfortunately, there are currently no effective treatment methods nor early detection methods. Furthermore, the disease underlying molecular mechanisms are poorly understood. Global bulk gene expression profiling suggested that the disease is governed by diverse transcriptional regulatory networks. Thus, to identify distinct transcriptional networks impacted into distinct neuronal populations in Alzheimer, we surveyed gene expression differences in over 25,000 single-nuclei collected from the brains of two Alzheimer's in disease patients in Braak stage I and II and age- and gender-matched controls hippocampal brain samples. APOE status was not measured for this study samples (as well as CERAD and THAL scores). Our bioinformatic analysis identified discrete glial, immune, neuronal and vascular cell populations spanning Alzheimer's disease and controls. Astrocytes and microglia displayed the greatest transcriptomic impacts, with the induction of both shared and distinct gene programs.
    MeSH term(s) Humans ; Alzheimer Disease/metabolism ; Brain/metabolism ; Neurons/metabolism ; Microglia/metabolism ; Sequence Analysis, RNA
    Language English
    Publishing date 2023-02-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0277630
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top